Clinical trial
A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination With BMS-936558 (Anti-PD-1) in Subjects With Advanced or Metastatic Solid Tumors
NCT01629758 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination With BMS-936558 (Anti-PD-1) in Subjects With Advanced or Metastatic Solid Tumors
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 30, 2012
- Completion date
- December 31, 2014
- Enrollment
- 33 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.